Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Asimadoline hydrochloride (EMD-61753 hydrochloride) is a κ-opioid receptor agonist potentially for the treatment of pruritus. Asimadoline hydrochloride has also been shown to be used in the treatment of irritable bowel syndrome.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
2 mg | In stock | $ 41.00 | |
5 mg | In stock | $ 67.00 | |
10 mg | In stock | $ 127.00 | |
25 mg | In stock | $ 297.00 | |
50 mg | In stock | $ 449.00 | |
100 mg | In stock | $ 658.00 | |
500 mg | In stock | $ 1,370.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 74.00 |
Description | Asimadoline hydrochloride (EMD-61753 hydrochloride) is a κ-opioid receptor agonist potentially for the treatment of pruritus. Asimadoline hydrochloride has also been shown to be used in the treatment of irritable bowel syndrome. |
Targets&IC50 | κ opioid (human recombinant):1.2 nM (EC50), κ opioid (Guinea pig):5.6 nM (EC50) |
In vitro | The IC50 for Asimadoline binding to μ-opioid receptors is 3 μM and to δ-opioid receptors is 0.7 μM. At high concentrations, Asimadoline demonstrates spasmolytic action against 400 μM barium chloride in the rat duodenum (IC50: 4.2 μM), suggesting that Asimadoline may block the direct stimulant effects of barium on smooth muscle through mechanisms that are not identified[1]. |
In vivo | The metabolism of Asimadoline is rapid and appears similar in animals and man. The absorption rate following oral administration is 80% in rats and >90% in dogs and monkeys. Asimadoline has peripheral anti-inflammatory actions that are partly mediated through an increase in joint fluid substance P levels[1]. Treatment with Asimadoline (5 mg/kg/day i.p.) produces marked (and sustained) attenuation of the disease with all three-time regimes[2]. |
Animal Research | Asimadoline (5 mg/kg/day, n=10 per group) or vehicle (2 mL/kg/day, n=10) is administered to DA rats by i.p. injection twice daily (i) during the primary inflammatory phase (days 1–3); (ii) once the disease is established (days 13–21); or (iii) throughout the entire time course (days 1-21). Non-arthritic control animals receive Asimadoline (5 mg/kg/day, n=5) or vehicle (2 mL/kg/day, n=5) by i.p. injection twice daily. In all cases, disease parameters are assessed. In this experiment, the SP content of joint tissue is assessed only after the rats are killed (day 21)[2]. |
Synonyms | EMD-61753 hydrochloride |
Molecular Weight | 451.01 |
Formula | C27H31ClN2O2 |
CAS No. | 185951-07-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (133.03 mM), Heating is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Asimadoline hydrochloride 185951-07-9 Endocrinology/Hormones GPCR/G Protein Neuroscience Opioid Receptor syndrome bowel diabetic EMD61753 EMD-61753 hydrochloride Asimadoline irritable κ-opioid δ-opioid EMD 61753 inhibit EMD61753 Hydrochloride Asimadoline Hydrochloride EMD-61753 EMD-61753 Hydrochloride μ-opioid allodynia EMD 61753 Hydrochloride Inhibitor inhibitor